Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Mylan Suffers Several Setbacks: What's in Store in 2H18?

Mounting competition and recent setbacks cast a pall over Mylan's (MYL) near-term performance.

    AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma

    AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.

      5 Reasons Why You Should Add Lilly Stock to Your Portfolio

      Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

        Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco

        The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.

          Mylan Suffers a Blow as Teva Gets FDA Nod for EpiPen Generic

          Mylan (MYL) suffers another setback as Teva wins the FDA approval of first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions.

            Teva Gets FDA Nod for First Generic Version of Mylan's EpiPen

            Teva (TEVA) gains FDA approval for the first generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment.

              Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

              Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

                Benjamin Rains headshot

                Invest Like Buffett & Berkshire With These Top Stock Picks

                Warren Buffett has for years been looked at as an investment icon, while maintaining a relatively simple mantra. Buffett and Berkshire Hathaway (BRK.B) have long tried to invest in companies that both the Oracle of Omaha and the conglomerate understand. This sounds easy enough, but what are some of Buffett's most recent investments?

                  Here's Why Lilly (LLY) Stock is Up 15% Since Q2 Earnings

                  Eli Lilly's (LLY) stock is up 15% since announcement of earnings in July. Let us have a look at the reasons for the same.

                    BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down

                    BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.

                      Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2

                      Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.

                        TEVA vs. TLGT: Which Stock Is the Better Value Option?

                        TEVA vs. TLGT: Which Stock Is the Better Value Option?

                          Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?

                          Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).

                            Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down

                            Teva's (TEVA) shares dip on mixed second-quarter results. The company maintains its 2018 sales guidance while raising the earnings outlook.

                              Company News For Aug 3, 2018

                              Companies in the news are: CI, TSLA, TEVA and REGN

                                Teva (TEVA) Beats on Q2 Earnings, Misses Sales, Shares Dip

                                Teva's (TEVA) second-quarter earnings beat estimates but sales miss expectations. Teva maintains its 2018 sales guidance while raising the earnings outlook. Shares dip in pre-market trading

                                  Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?

                                  While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

                                    Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q1

                                    Dr Reddy's (RDY) surpasses both earnings and sales year over year in the first quarter of fiscal 2019.

                                      Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up

                                      Amgen (AMGN) impresses with better-than-estimated second-quarter results and raises its outlook for the full year. Shares rise in after-hours trading.

                                        Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

                                        Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

                                          Tirthankar Chakraborty headshot

                                          4 Warren Buffett Stocks to Buy in Q2 Earnings

                                          We highlight four of the Oracle of Omaha's sought-after companies that are likely to report upbeat second-quarter earnings.

                                            Has Teva Pharmaceutical Industries (TEVA) Outpaced Other Medical Stocks This Year?

                                            Is (TEVA) Outperforming Other Medical Stocks This Year?

                                              TEVA or AKRX: Which Is the Better Value Stock Right Now?

                                              TEVA vs. AKRX: Which Stock Is the Better Value Option?

                                                Lilly Wins Favorable Ruling From U.S. Court in Alimta Row

                                                Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.

                                                  Teva to Discontinue a Fremanezumab Study on Cluster Headache

                                                  Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.